纳武利尤单抗联合艾日布林治疗HER2阴性转移性乳腺癌的临床活性:一项IB/II期研究(KCSG BR18-16)
该平行II期研究在韩国10家学术医院前瞻性纳入90例复发/转移性HER2阴性乳腺癌患者,其中激素受体阳性/HER2阴性(HR+HER2-)45例、三阴性乳腺癌(TNBC)45例,接受纳武利尤单抗360 mg联合艾日布林1.4 mg/m2治疗。HR+HER2-组和TNBC组6个月无进展生存率分别为47.2%和25.1%,客观缓解率分别为53.3%和28.9%,PD-L1表达与疗效无显著关联,安全性可耐受。
要点
- HR+HER2-组6个月PFS率47.2%,TNBC组25.1%,中位PFS分别为5.6个月和3.0个月。
- HR+HER2-组ORR为53.3%(CR 0例,PR 24例),TNBC组ORR为28.9%(CR 1例,PR 12例)。
- PD-L1阳性(表达≥1%)与阴性肿瘤ORR相似,中性粒细胞减少为最常见3/4级不良事件。
核心结论
- 纳武利尤单抗联合艾日布林在经治HER2阴性转移性乳腺癌中显示出有前景的疗效和可耐受的安全性。
研究设计与样本
- 平行II期研究,前瞻性纳入韩国10家学术医院成人组织学确诊的复发/转移性HR+HER2-或TNBC患者,HR+HER2-组45例、TNBC组45例。
- 治疗方案为每3周第1天纳武利尤单抗360 mg联合第1天和第8天艾日布林1.4 mg/m2,直至疾病进展或不可耐受毒性。
- 主要终点为研究者评估的各亚型6个月无进展生存率,次要终点包括研究者评估的ORR(按RECIST 1.1)、疾病控制率、总生存和治疗毒性,并分析PD-L1表达与疗效的关联。
主要发现
- HR+HER2-组6个月PFS率为47.2%,TNBC组为25.1%。
- HR+HER2-组中位PFS为5.6个月(95%CI:5.3-7.4),TNBC组为3.0个月(95%CI:2.1-5.2)。
- HR+HER2-组ORR为53.3%(CR 0例,PR 24例),TNBC组ORR为28.9%(CR 1例,PR 12例)。
- PD-L1阳性(表达≥1%)与PD-L1阴性肿瘤的ORR相似:HR+HER2-组为50% vs 53.8%,TNBC组为30.8% vs 29.0%。
- 中性粒细胞减少为最常见3/4级不良事件,最常见免疫相关不良事件为1/2级甲状腺功能减退和瘙痒,5例患者因免疫相关不良事件终止治疗。
关键数值与推荐
- HR+HER2-组6个月PFS率47.2%,TNBC组25.1%。
- HR+HER2-组中位PFS 5.6个月(95%CI:5.3-7.4),TNBC组3.0个月(95%CI:2.1-5.2)。
- HR+HER2-组ORR 53.3%(CR 0例,PR 24例),TNBC组ORR 28.9%(CR 1例,PR 12例)。
- PD-L1阳性(表达≥1%)与阴性肿瘤ORR:HR+HER2-组50% vs 53.8%,TNBC组30.8% vs 29.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: We evaluated the efficacy and safety of nivolumab and eribulin combination therapy for metastatic breast cancer (BC) in Asian populations. METHODS: In this parallel phase II study, adult patients with histologically confirmed recurrent/metastatic hormone receptor-positive/HER2-negative (HR+HER2-) or triple-negative BC (TNBC) were prospectively enroled from 10 academic hospitals in Korea (ClinicalTrials.gov Identifier: NCT04061863). They received nivolumab (360 mg) on day 1 plus eribulin (1.4 mg/m2) on days 1 and 8 every 3 weeks until disease progression or intolerable toxicity. The primary endpoint was the investigator-assessed 6-month progression-free survival (PFS) rate in each subtype. Secondary endpoints included investigator-assessed objective response rate (ORR) as per Response Evaluation Criteria in Advanced Solid Tumors version 1.1, disease control rate, overall survival, and treatment toxicity. The association between PD-L1 expression and efficacy was investigated. RESULTS: Forty-five patients with HR+HER2- BC and 45 with TNBC were enroled. Their median age was 51 (range, 31-71) years, and 74 (82.2%) received one or two prior treatments before enrolment. Six-month PFS was 47.2% and 25.1% in the HR+HER2- and TNBC cohorts, respectively. Median PFS was 5.6 (95% confidence interval [CI]: 5.3-7.4) and 3.0 (95% CI: 2.1-5.2) months in the HR+HER2- and TNBC groups, respectively. ORRs were 53.3% (complete response [CR]: 0, partial response [PR]: 24) and 28.9% (CR: 1, PR: 12). Patients with PD-L1+ tumours (PD-L1 expression ≥1%) and PD-L1- tumours (ORR 50% versus 53.8% in HR+HER2-, 30.8% versus 29.0% in TNBC) had similar ORRs. Neutropenia was the most common grade 3/4 adverse event; the most common immune-related adverse events (AEs) were grades 1/2 hypothyroidism and pruritus. Five patients discontinued therapy because of immune-related AEs. CONCLUSION: Nivolumab plus eribulin showed promising efficacy and tolerable safety in previously treated HER2- metastatic BC. TRIAL REGISTRATION: NCT04061863.
引用
- Kim SH, Im SA, Suh KJ, et al. Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16). Eur J Cancer. 2023. PMID: 37890351. doi:10.1016/j.ejca.2023.113386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。